)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Nuvation Bio
Nuvation Bio (NUVB) investor relations material
Nuvation Bio 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Key product updates and clinical progress
Ibtrozi (taletrectinib) is approved in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer, showing an 89% response rate and 50-month duration of response, outperforming competitors.
Safusidenib, a mutant IDH1 inhibitor, is in pivotal studies for gliomas, demonstrating superior progression-free survival and response rates compared to vorasidenib, with unique immune-related adverse events.
NUV-868, a BD2-selective BET inhibitor, has completed phase I, and a novel drug-drug conjugate (DDC) platform is in preclinical development.
Financial position and strategic partnerships
Cash balance stands at $589 million, expected to rise to $620 million with a near-term milestone from Eisai.
Recent Eisai deal for Europe and select territories includes $60 million upfront, $30 million milestone, and high double-digit royalties.
Additional partnerships in China and Japan have generated $120 million upfront and $520 million in milestones.
Operating expenses are stable after discontinuing NUV-1511, freeing capital for potential acquisitions of late-stage or commercial assets.
Market opportunity and growth drivers
U.S. market for ROS1-positive NSCLC estimated at 3,000 patients annually, with potential to reach $5 billion as RNA testing becomes standard.
Ibtrozi is already the market leader in ROS1 TKIs, with 6x faster launch than competitors and 90% coverage to label.
NCCN guidelines now contraindicate IO chemo for ROS1 lung cancer, favoring ROS1 agents and supporting further market share gains.
Safusidenib targets a glioma market with significant prevalence due to long patient survival, and early data suggest a strong competitive profile.
IBTROZI: Strategy to capture full market potential
Safusidenib: Impact of early ORR data on strategy
Capital deployment: M&A focus for future growth
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nuvation Bio earnings date
Q4 20254 Mar, 2026
Nuvation Bio
Next Nuvation Bio earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to addressing some of the most significant unmet needs in oncology. The company is focused on the development of differentiated and novel therapeutic candidates, aiming to significantly change the practice of oncology through medicines that offer meaningful improvements in quality of life and survival for cancer patients. Nuvation Bio's approach includes a wholly-owned deep pipeline of six differentiated and novel investigational oncology therapeutic candidates targeting critical pathways that cancer cells use for growth. The company is headquartered in New York, New York, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage